Skip to content

Clinical trials

Arthritis, Rheumatoid trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Arthritis, Rheumatoid Country / region: China Clear all

240 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20031
20043
20056
20063
20074
20082
20093
20103
20111
201214
20135
201417
201511
20167
201712
201815
201914
20207
202115
202218
202317
202410
202535
202615

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed101
Unknown status67
Recruiting43
Terminated10
Active, not recruiting7
Not yet recruiting6
Enrolling by invitation3
Withdrawn2
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Guang'anmen Hospital of China Academy of Chinese Medical Sciences11
Hoffmann-La Roche11
Peking Union Medical College Hospital10
Peking University People's Hospital10
Chinese University of Hong Kong9
Jiangsu HengRui Medicine Co., Ltd.8
AbbVie6
Pfizer6
Qilu Hospital of Shandong University6
Chengdu PLA General Hospital5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Arthritis, Rheumatoid240
Lupus Erythematosus, Systemic13
Scleroderma, Systemic12
Osteoarthritis10
Myositis8
Autoimmune Diseases7
Arthritis6
Lung Diseases, Interstitial5
Connective Tissue Diseases4
Osteonecrosis4

Trials

Showing 76 to 100 of 240. Each trial links to its page on Pharma Observatory.

140 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.